APOA2 and pancreatic neoplasm: The sensitivities of the combination assay with apoA2-ATQ/AT and CA19-9 for stages I, IA, IB, IIB, I/II, and TS1 of pancreatic cancer were 63.2%, 62.5%, 63.6%, 81.8%, 70.0%, and 66.7%, respectively.